ArticleArthritis & rheumatology (Hoboken, N.J.)2023
Association of
Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- Pooled it
- Differential Vascular Response to Corticosteroid Therapy in Takayasu Arteritis Revealed by Serial FDG-PET Imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- Imaging-guided stratification in giant cell arteritis: prognostic and therapeutic implications.Therapeutic advances in musculoskeletal disease · 2026Review
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.Current rheumatology reports · 2025Review
- The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.Biomolecules · 2025Review
- New avenues in childhood vasculitis.Pediatric rheumatology online journal · 2025Review
- Association of PET vascular activity score with Takayasu's arteritis angiographic progression.European journal of nuclear medicine and molecular imaging · 2025Observational
- Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025Article
- Comment on: Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission.Rheumatology (Oxford, England) · 2025Article
- Positron Emission Tomography in Takayasu Arteritis: A Review Including Patterns of Vascular Involvement Across Modalities and Regions.Journal of clinical medicine · 2025Review
- Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.RMD open · 2024Article
- New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis.RMD open · 2024Article
- Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024Review
- The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.Frontiers in medicine · 2024Article
- What is new in imaging to assist in the diagnosis of giant cell arteritis and Takayasu's arteritis since the EULAR and ACR/VF recommendations?Frontiers in medicine · 2024Review
- An overview of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in giant cell arteritis.Frontiers in medicine · 2024Review
- Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study.Seminars in arthritis and rheumatism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo assess whether vascular activity seen on
methodsPatients with LVV were recruited into a prospective cohort. All patients underwent magnetic resonance angiography or computed tomography angiography and FDG-PET imaging. Follow-up imaging using the same imaging modalities was obtained ≥6 months later per a standardized imaging protocol. Arterial damage, defined as stenosis, occlusion, or aneurysm, and corresponding FDG uptake were evaluated in 17 arterial territories. On follow-up, development of new lesions was recorded, and existing lesions were characterized as improved, worsened, or unchanged.
resultsA total of 1,091 arterial territories from 70 patients with LVV (38 patients with Takayasu arteritis, 32 patients with giant cell arteritis) were evaluated. Over a median 1.6 years of follow-up, new lesions developed only in 8 arterial territories in 5 patients with Takayasu arteritis. Arterial lesions improved in 16 territories and worsened in 6 territories. Most arterial territories that did not have vascular activity on FDG-PET scan at baseline had no angiographic change over the follow-up period (787 [99%] of 793). Few territories with baseline FDG-PET activity had angiographic change over time (24 [8%] of 298), but of the territories that developed angiographic change, 80% had FDG-PET activity at baseline. Within the same patient, an arterial territory with baseline FDG-PET activity had significantly increased risk for angiographic change compared to a paired arterial territory without FDG-PET activity (odds ratio 19.49 [95% confidence interval 2.44-156.02]; P < 0.01). Concomitant edema and wall thickening further increased risk for angiographic change.
conclusionDevelopment of angiographic change was infrequent in this cohort of patients with LVV. A lack of baseline FDG-PET activity was strongly associated with stable angiographic disease. In cases of angiographic progression, change was preceded by the presence of FDG-PET activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.